Proteomics Lab, National Centre for Cell Science, Ganeshkhind, Pune-411007, MH, India.
Savitribai Phule Pune University, Ganeshkhind, Pune-411007, MH, India.
Curr Top Med Chem. 2018;18(30):2584-2598. doi: 10.2174/1568026619666181130111202.
Chemoresistance is one of the major hurdles in cancer treatment leading to recurrence of cancer and affects the overall survival of patients. Cancer chemoresistance can be associated with various phenomena including modulation of vital cellular pathways. Unrevealing these alterations could provide a better understanding of chemoresistance and assist in the identification of new targets to overcome it. Recent advances in the field of proteomics and metabolomics have substantially helped in the identification of potential targets for chemoresistance in various cancers. This review highlights the potential of proteomics and metabolomics research to explore the putative targets associated with cancer chemoresistance with a special focus on Multiple Myeloma (MM). MM is a type of hematological malignancy which constitutes about 13% of all blood cell cancers. The therapeutic advancements for MM have increased the median overall survival rate to over 3-fold in the last one and half decade. Although in recent times, significant improvements in the overall survival rate of MM are achieved, MM remains an incurable disease with unpredictable refractory mechanisms. In spite of therapeutic advances, chemoresistance thrives to be a major hurdle in the treatment of multiple myeloma which demands a better understanding of chemoresistance. In this review, we have attempted to highlight the potential applications of proteomics and metabolomics research in the understanding of chemoresistance in MM.
化疗耐药性是癌症治疗中的主要障碍之一，导致癌症复发，并影响患者的整体生存。癌症化疗耐药性可能与多种现象相关，包括重要细胞途径的调节。揭示这些改变可以更好地了解化疗耐药性，并有助于确定克服它的新靶点。蛋白质组学和代谢组学领域的最新进展极大地帮助确定了各种癌症中化疗耐药性的潜在靶点。本综述强调了蛋白质组学和代谢组学研究在探索与癌症化疗耐药性相关的假定靶点方面的潜力，特别关注多发性骨髓瘤 (MM)。MM 是一种血液恶性肿瘤，占所有血细胞癌的 13%左右。MM 的治疗进展使过去十五年中 MM 的中位总生存率提高了三倍以上。尽管最近 MM 的总体生存率有了显著提高，但 MM 仍然是一种无法治愈的疾病，其难治机制不可预测。尽管有治疗进展，但化疗耐药性仍然是多发性骨髓瘤治疗中的主要障碍，需要更好地了解化疗耐药性。在本综述中，我们试图强调蛋白质组学和代谢组学研究在理解 MM 中化疗耐药性方面的潜在应用。
